Home/ Stocks/ NERV

Minerva Neurosciences, Inc

NERV XNAS

$5.88 -0.25 (-4.00%) ▼ 15-min delayed

Open

$6.10

High

$6.10

Low

$5.86

Volume

74.7K

Market Cap

$273.94M

About Minerva Neurosciences, Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 7 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-125,404,384	$-2.86
FY 2025	$0	$-293,423,177	$-34.67
Q3 2025	$0	$-2,743,954	$-0.36
Q2 2025	$0	$-3,258,588	$-0.43

Related Market News

No specific coverage for NERV yet. Check out our latest market news or earnings calendar.

Get NERV Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Minerva Neurosciences, Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.